Investigational ADC Franchise
The investigational Antibody Drug Conjugate (ADC) Franchise of the Daiichi Sankyo Cancer Enterprise is built around our proprietary ADC technology, which is being researched across multiple types of cancer. Our proprietary linker and payload technologies have been specifically designed to potentially address various limitations of two critical components of an ADC: the payload and linker.
Daiichi Sankyo Proprietary ADC Technology
ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy directly to
cancer cells. An ADC consists of three components:
- a monoclonal antibody
- a cytotoxic chemotherapy payload
- a linker that joins the two together
Using expertise in both protein engineering and medicinal chemistry, our team of exceptional scientists has methodically designed proprietary ADC technology to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way that chemotherapy is commonly delivered. The cornerstone of our ADC Franchise is a proprietary payload and linker-payload technology, which consists of:
- Payload: DXd, a novel topoisomerase I inhibitor
- Linker: A proprietary tetrapeptide-based linker that joins the antibody and payload together, and is designed to be broken down by lysosomal enzymes such as cathepsins, which are highly expressed in tumor cells
Our investigational ADC Franchise currently consists of seven novel ADCs, including DS-8201 in pivotal phase 2 clinical development; U3-1402 in phase 1/2 clinical development, DS-1062 in phase 1 development; DS-7300, DS-6157 and DS-6000 in preclinical development; and TA-MUC1 in discovery.
We are open to partnership opportunities with external companies to combine our linker-payload technology with other monoclonal antibodies as well as collaborations with other oncology compounds to study in combination with our ADC assets.
These are investigational agents and have not been approved by the EMA, FDA or any other worldwide regulatory agency as a treatment for any indication. Safety and efficacy have not been established.